BackCERo Therapeutics Holdings - Warrants (13/02/2029) Overview
CERo Therapeutics Holdings Inc. - Warrants (13/02/2029)

CERo Therapeutics Holdings - Warrants (13/02/2029) Return on Equity

Latest ROE for CERo Therapeutics Holdings - Warrants (13/02/2029): 416.3% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

416.30%

Return on Equity

416.30%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

CERo Therapeutics Holdings - Warrants (13/02/2029) (CEROW) FAQ

The latest ROE for CEROW is 416.3%. That is above the sector sector average of 11.73%. Investors often review this figure alongside CERo Therapeutics Holdings - Warrants (13/02/2029)'s historical trend and sector peers before judging valuation or financial health.

Against its sector companies, CEROW currently prints 416.3% for ROE, while the sector average sits near 11.73%. That is roughly 3447.9% above the sector mean. Large gaps often invite a closer look at CERo Therapeutics Holdings - Warrants (13/02/2029)'s growth, margins, and balance sheet.

Return on Equity shows how effectively CERo Therapeutics Holdings - Warrants (13/02/2029) converts resources into returns. At 416.3%, CEROW may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CEROW's ROE (416.3%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.